OCA – Patient Worthy

source: pixabay.com

Intercept Withdraws Application for Obeticholic Acid for NASH in Europe

Post author:Kendall Mason
Post published:December 17, 2021
Post category:Nonalcoholic steatohepatitis

Intercept has withdrawn its application for obeticholic acid (OCA) as a treatment for nonalcoholic steatohepatitis (NASH) in Europe. This decision comes after the FDA rejected the company's application in the…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More